Optimizing panel-based tumor mutational burden (TMB) measurement-Reference-Cited by-同舟云学术

Optimizing panel-based tumor mutational burden (TMB) measurement

Published:2019-09 Issue:9 Volume:30 Page:1496-1506
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Budczies J.^ORCID,Allgäuer M.,Litchfield K.,Rempel E.,Christopoulos P.,Kazdal D.,Endris V.,Thomas M.,Fröhling S.,Peters S.,Swanton C.,Schirmacher P.,Stenzinger A.

Funder

Novartis

Berlin Mathematical School

Boehringer Ingelheim

Roche

Daiichi-Sankyo

Takeda Pharmaceutical Company

Celgene

Merck Sharp and Dohme

AbbVie

Chugai Pharmaceutical

AstraZeneca

Clovis Oncology

Meso Scale Diagnostics

Eli Lilly and Company

Pfizer

Amgen

Bristol-Myers Squibb

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz205/29103834/mdz205.pdf

Reference37 articles.

1. Immune surveillance of tumors;Swann;J Clin Invest,2007

2. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012

3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

4. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?;Kerr;J Thorac Oncol,2015

5. TCR repertoires of intratumoral T-cell subsets;Linnemann;Immunol Rev,2014

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multi-task deep learning model based on comprehensive feature integration and self-attention mechanism for predicting response to anti-PD1/PD-L1;International Immunopharmacology;2024-12

2. Benchmarking Whole Exome Sequencing in the German Network for Personalized Medicine;European Journal of Cancer;2024-09

3. Tumour mutational burden: clinical utility, challenges and emerging improvements;Nature Reviews Clinical Oncology;2024-08-27

4. Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma;Pediatric Blood & Cancer;2024-07-05

5. Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer;Frontiers in Oncology;2024-06-14